MX370430B - Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos. - Google Patents

Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos.

Info

Publication number
MX370430B
MX370430B MX2016016720A MX2016016720A MX370430B MX 370430 B MX370430 B MX 370430B MX 2016016720 A MX2016016720 A MX 2016016720A MX 2016016720 A MX2016016720 A MX 2016016720A MX 370430 B MX370430 B MX 370430B
Authority
MX
Mexico
Prior art keywords
muscarinic antagonists
horses
treatment
airway disease
combinations
Prior art date
Application number
MX2016016720A
Other languages
English (en)
Other versions
MX2016016720A (es
Inventor
Aven Michael
Albrecht Balazs
Lamar Janine
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2016016720A publication Critical patent/MX2016016720A/es
Publication of MX370430B publication Critical patent/MX370430B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A61K35/06—Mineral oils, e.g. paraffinic oils or aromatic oils based on aromatic hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2250/00—Specially adapted for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al campo de la medicina, en particular al campo de la medicina veterinaria. La invención se refiere, específicamente, a antagonistas muscarínicos (incluyendo antagonistas muscarínicos de larga acción (LAMAs) para el tratamiento de enfermedades de las vías respiratorias tales como la enfermedad pulmonar, preferiblemente la obstrucción recurrente de las vías respiratorias (RAO), enfermedad pulmonar obstructiva asociada al pasto del verano (SPAOPD) y la enfermedad inflamatoria de las vías respiratorias (IAD) en animales, preferiblemente equinos tales como caballos.
MX2016016720A 2014-06-18 2015-06-15 Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos. MX370430B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14172925 2014-06-18
PCT/EP2015/063265 WO2015193213A1 (en) 2014-06-18 2015-06-15 Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

Publications (2)

Publication Number Publication Date
MX2016016720A MX2016016720A (es) 2017-04-13
MX370430B true MX370430B (es) 2019-12-13

Family

ID=50972546

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016016720A MX370430B (es) 2014-06-18 2015-06-15 Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos.
MX2019014935A MX2019014935A (es) 2014-06-18 2016-12-15 Antagonistas muscarinicos y sus combinaciones para el tratamiento de enfermedades de las vias respiratorias en caballos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019014935A MX2019014935A (es) 2014-06-18 2016-12-15 Antagonistas muscarinicos y sus combinaciones para el tratamiento de enfermedades de las vias respiratorias en caballos.

Country Status (17)

Country Link
US (3) US9474747B2 (es)
EP (2) EP3157522B1 (es)
KR (1) KR102618119B1 (es)
AU (2) AU2015276310B2 (es)
CA (1) CA2952701C (es)
CY (1) CY1122335T1 (es)
DK (1) DK3157522T3 (es)
ES (1) ES2759247T3 (es)
HR (1) HRP20192010T1 (es)
HU (1) HUE051527T2 (es)
LT (1) LT3157522T (es)
MX (2) MX370430B (es)
PL (1) PL3157522T3 (es)
PT (1) PT3157522T (es)
RS (1) RS59613B1 (es)
SI (1) SI3157522T1 (es)
WO (1) WO2015193213A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2934479T1 (sl) 2012-12-21 2019-01-31 Boehringer Ingelheim Vetmedica Gmbh Ciklezonid za zdravljenje bolezni dihalnih poti pri konjih
EP2934544B1 (en) 2012-12-21 2018-11-07 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical formulation comprising ciclesonide
MX370430B (es) 2014-06-18 2019-12-13 Boehringer Ingelheim Vetmedica Gmbh Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos.
CN111840256A (zh) * 2019-04-29 2020-10-30 上海谷森医药有限公司 一种雾化吸入剂及其制备方法
WO2020237151A1 (en) * 2019-05-23 2020-11-26 Huang Cai Gu Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide
CN115835885B (zh) * 2020-06-23 2025-02-07 广州谷森制药有限公司 包含奥达特罗和布地奈德的药物组合物的制备
US20230270754A1 (en) 2020-07-31 2023-08-31 Chemo Research, S.L. Combination therapy for inhalation administration
WO2022073009A1 (en) 2020-09-29 2022-04-07 iPharma Labs, Inc. Liquid formulations of indacaterol

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5954049A (en) 1991-10-15 1999-09-21 Trudell Medical Limited Equine mask with MDI adapter
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5823179A (en) * 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6706726B2 (en) 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
DE10050994A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US6904908B2 (en) * 2002-05-21 2005-06-14 Trudell Medical International Visual indicator for an aerosol medication delivery apparatus and system
US7244742B2 (en) 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US20040053902A1 (en) * 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
EP1635844A1 (en) 2003-05-22 2006-03-22 ALTANA Pharma AG Salmeterol and ciclesonide combination
US20050020692A1 (en) * 2003-07-24 2005-01-27 Ciofalo Vincent B. Treatment of heaves
PL1670482T5 (pl) 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
EP1740188A1 (en) 2004-04-20 2007-01-10 Altana Pharma AG Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
EP1763344A1 (en) 2004-06-29 2007-03-21 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising steroids and an anticholinergic
DE102004056579A1 (de) * 2004-11-23 2006-05-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Salmeterol und ein Steroid
US20070028923A1 (en) 2005-08-08 2007-02-08 Patrick Souris Tip-laryngeal airway
UY30543A1 (es) 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
RU2477661C2 (ru) 2008-10-30 2013-03-20 Сименс Акциенгезелльшафт Способ регулирования толщины при выходе раската, который проходит через многоклетьевую линию прокатного стана, разомкнутое и/или замкнутое управляющее устройство и прокатный стан
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP2012530567A (ja) * 2009-06-25 2012-12-06 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入器
WO2014007766A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
EA201590030A1 (ru) * 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
WO2014016548A2 (en) * 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
US9539408B2 (en) * 2012-10-31 2017-01-10 Trudell Medical International Nebulizer apparatus
SI2934479T1 (sl) 2012-12-21 2019-01-31 Boehringer Ingelheim Vetmedica Gmbh Ciklezonid za zdravljenje bolezni dihalnih poti pri konjih
EP2934544B1 (en) * 2012-12-21 2018-11-07 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical formulation comprising ciclesonide
SI3035885T1 (sl) * 2013-08-20 2020-04-30 Boehringer Ingelheim Vetmedica Gmbh Inhalator
ES2837948T3 (es) * 2013-08-20 2021-07-01 Boehringer Ingelheim Vetmedica Gmbh Inhalador
MX370430B (es) 2014-06-18 2019-12-13 Boehringer Ingelheim Vetmedica Gmbh Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos.

Also Published As

Publication number Publication date
AU2015276310A1 (en) 2016-12-08
SI3157522T1 (sl) 2020-01-31
US20190262329A1 (en) 2019-08-29
US9474747B2 (en) 2016-10-25
AU2020202402B2 (en) 2021-05-27
US10682345B2 (en) 2020-06-16
WO2015193213A1 (en) 2015-12-23
MX2019014935A (es) 2020-02-13
CA2952701C (en) 2023-09-19
EP3157522B1 (en) 2019-09-04
AU2020202402A1 (en) 2020-04-30
KR20170016986A (ko) 2017-02-14
DK3157522T3 (da) 2019-12-09
AU2015276310B2 (en) 2020-01-16
HRP20192010T1 (hr) 2020-02-07
ES2759247T3 (es) 2020-05-08
LT3157522T (lt) 2019-11-25
HUE051527T2 (hu) 2021-03-01
EP3157522A1 (en) 2017-04-26
KR102618119B1 (ko) 2023-12-27
CA2952701A1 (en) 2015-12-23
PL3157522T3 (pl) 2020-03-31
EP3603640A1 (en) 2020-02-05
US20150366855A1 (en) 2015-12-24
MX2016016720A (es) 2017-04-13
US10342789B2 (en) 2019-07-09
CY1122335T1 (el) 2021-01-27
US20170007593A1 (en) 2017-01-12
PT3157522T (pt) 2019-12-13
RS59613B1 (sr) 2020-01-31

Similar Documents

Publication Publication Date Title
MX2019014935A (es) Antagonistas muscarinicos y sus combinaciones para el tratamiento de enfermedades de las vias respiratorias en caballos.
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
IL249061B (en) Combination, composition, and method of administering the combination or composition to animals
LT3674298T (lt) Pakeistieji indazolai, jų gavimo būdas, juos turinčios farmacinės kompozicijos ir jų panaudojimas vaistų gamybai
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EP3250048A4 (en) Oligosaccharide compositions for use animal feed and methods of producing thereof
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
WO2014151456A3 (en) Treatment of inflammatory diseases
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
HRP20190573T1 (hr) Piranokromenil fenol derivat, i farmaceutska kompozicija za liječenje metaboličkog sindroma ili inflamatorne bolesti
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
NZ706573A (en) Ciclesonide for the treatment of airway disease in horses
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
MX2017001293A (es) Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
EP3506768B8 (en) Milk replacer composition comprising 2'-fucosyllactose for use in the treatment or prevention of gastro-intestinal diseases of production animals
MX2017009452A (es) Agentes de imagenologia para tomografia de emision de positrones (pet).
AU2014353885A8 (en) Prevention and treatment of toxicosis
WO2016083315A8 (en) Use of ox1r antagonists for the treatment of inflammatory bowel diseases

Legal Events

Date Code Title Description
FG Grant or registration